Qian Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Qian Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dan Zhang
Department of Radiation Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
1 shared publication - Dong Li
Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China
1 shared publication - Jing Sun
Department of Radiation Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
1 shared publication - Jun Jia
Department of Radiation Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
1 shared publication - JunQiang Ding
Department of Radiation Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
1 shared publication - Xuezhang Duan
Department of Radiation Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 8 November 2022
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-8
Stereotactic body radiation therapy as an effective local treatment for advanced hepatocellular carcinoma patients with inferior vena cava and right atrial tumor thrombus
Background: The aim of our study was to evaluate the curative effect and safety of stereotactic body radiation therapy (SBRT) in treating hepatocellular carcinoma (HCC) patients with inferior vena cava (IVCTT) and right atrial tumor thrombus (RATT). Methods: This retrospective study included fifteen advanced HCC patients with IVCTT and RATT who were treated with SBRT between 2013 and 2020. The prescribed dose delivered to the tumor was 45–50 Gy/7–10 fx. We report their treatment responses according to survival time and toxicities. Results: For these patients, the median follow-up time was 15 months (2–52 months). Local tumor control rates of the treated area were 80% at the time of death or at the last follow-up. The 6-month, 12-month, 18-month and 24-month OS rates were 80.0%, 60.0%, 33.3% and 26.7%, respectively. None of these patients died from the toxicity outcomes and complications of SBRT. Conclusion: SBRT is an effective option for advanced HCC patients with IVCTT and RATT.
- 8 November 2022
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-8
Open AccessStereotactic body radiation therapy as an effective local treatment for advanced hepatocellular carcinoma patients with inferior vena cava and right atrial tumor thrombus
Background: The aim of our study was to evaluate the curative effect and safety of stereotactic body radiation therapy (SBRT) in treating hepatocellular carcinoma (HCC) patients with inferior vena cava (IVCTT) and right atrial tumor thrombus (RATT). Methods: This retrospective study included fifteen advanced HCC patients with IVCTT and RATT who were treated with SBRT between 2013 and 2020. The prescribed dose delivered to the tumor was 45–50 Gy/7–10 fx. We report their treatment responses according to survival time and toxicities. Results: For these patients, the median follow-up time was 15 months (2–52 months). Local tumor control rates of the treated area were 80% at the time of death or at the last follow-up. The 6-month, 12-month, 18-month and 24-month OS rates were 80.0%, 60.0%, 33.3% and 26.7%, respectively. None of these patients died from the toxicity outcomes and complications of SBRT. Conclusion: SBRT is an effective option for advanced HCC patients with IVCTT and RATT.